{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=2+NRTIs&page=2", "query": { "intervention": "2 NRTIs", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=2+NRTIs&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-14T05:35:40.515Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00110305", "title": "A Study of TMC278 in Human Immunodeficiency Virus Type 1 Infected Patients, Who Are Not Treated With Antiretroviral Medicines", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Human Immunodeficiency Virus Type 1" ], "interventions": [ { "name": "TMC278 25 mg", "type": "DRUG" }, { "name": "TMC278 75 mg", "type": "DRUG" }, { "name": "TMC278 150 mg", "type": "DRUG" }, { "name": "Efavirenz", "type": "DRUG" }, { "name": "Non-nucleoside reverse transcriptase inhibitor (NRTIs)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tibotec Pharmaceuticals, Ireland", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 368, "start_date": "2005-06", "completion_date": "2011-12", "has_results": true, "last_update_posted_date": "2014-06-25", "last_synced_at": "2026-09-14T05:35:40.515Z", "location_count": 9, "location_summary": "Beverly Hills, California • Washington D.C., District of Columbia • Orlando, Florida + 6 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Orlando", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00110305" }, { "nct_id": "NCT04375800", "title": "Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Human Immunodeficiency Virus (HIV) Infection" ], "interventions": [ { "name": "Doravirine", "type": "DRUG" }, { "name": "2 NRTIs", "type": "DRUG" }, { "name": "DOR/3TC/TDF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Weeks", "maximum_age": "11 Years", "sex": "ALL", "summary": "4 Weeks to 11 Years" }, "enrollment_count": 84, "start_date": "2021-02-03", "completion_date": "2034-04-11", "has_results": false, "last_update_posted_date": "2026-07-08", "last_synced_at": "2026-09-14T05:35:40.515Z", "location_count": 2, "location_summary": "Aurora, Colorado • Atlanta, Georgia", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04375800" }, { "nct_id": "NCT02429791", "title": "Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-1)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "DTG 50 mg", "type": "DRUG" }, { "name": "RPV 25 mg", "type": "DRUG" }, { "name": "CAR", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 510, "start_date": "2015-04-14", "completion_date": "2023-05-30", "has_results": true, "last_update_posted_date": "2024-09-03", "last_synced_at": "2026-09-14T05:35:40.515Z", "location_count": 13, "location_summary": "Long Beach, California • Los Angeles, California • San Francisco, California + 9 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02429791" }, { "nct_id": "NCT01172535", "title": "A Phase II/III Trial of Lopinavir/Ritonavir Dosed According to the WHO Pediatric Weight Band Dosing Guidelines", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "HIV" ], "interventions": [ { "name": "Lopinavir/ritonavir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Weeks", "maximum_age": null, "sex": "ALL", "summary": "4 Weeks and older" }, "enrollment_count": 97, "start_date": "2010-11", "completion_date": "2013-12", "has_results": true, "last_update_posted_date": "2021-11-05", "last_synced_at": "2026-09-14T05:35:40.515Z", "location_count": 3, "location_summary": "La Jolla, California • Aurora, Colorado • Boston, Massachusetts", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01172535" }, { "nct_id": "NCT03739996", "title": "Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) for Viral Suppression in Adults Living With HIV-1", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Oral Cabotegravir (CAB)", "type": "DRUG" }, { "name": "Nucleoside Reverse Transcriptase Inhibitors (NRTIs)", "type": "DRUG" }, { "name": "Long-Acting Injectable Cabotegravir (CAB LA)", "type": "DRUG" }, { "name": "VRC07-523LS", "type": "BIOLOGICAL" }, { "name": "Standard of Care (SOC) ART", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 75, "start_date": "2019-12-31", "completion_date": "2024-04-29", "has_results": true, "last_update_posted_date": "2025-05-23", "last_synced_at": "2026-09-14T05:35:40.515Z", "location_count": 17, "location_summary": "Birmingham, Alabama • San Diego, California • San Francisco, California + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03739996" }, { "nct_id": "NCT02858401", "title": "Safety and Biological Activity of Vesatolimod in HIV-1 Infected, Virologically Suppressed Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "Vesatolimod", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "ARV regimen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2015-01-29", "completion_date": "2019-02-14", "has_results": true, "last_update_posted_date": "2020-02-21", "last_synced_at": "2026-09-14T05:35:40.515Z", "location_count": 8, "location_summary": "Los Angeles, California • San Diego, California • Ft. Pierce, Florida + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Ft. Pierce", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02858401" }, { "nct_id": "NCT06630299", "title": "Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV-1-Infection" ], "interventions": [ { "name": "ISL/LEN", "type": "DRUG" }, { "name": "Antiretroviral Combinations", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 600, "start_date": "2024-10-08", "completion_date": "2030-08", "has_results": false, "last_update_posted_date": "2026-05-29", "last_synced_at": "2026-09-14T05:35:40.515Z", "location_count": 49, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 41 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palm Springs", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06630299" }, { "nct_id": "NCT01363011", "title": "Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acquired Immunodeficiency Syndrome", "HIV Infections" ], "interventions": [ { "name": "E/C/F/TDF", "type": "DRUG" }, { "name": "COBI", "type": "DRUG" }, { "name": "ATV", "type": "DRUG" }, { "name": "DRV", "type": "DRUG" }, { "name": "NRTI", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 106, "start_date": "2011-05", "completion_date": "2015-02", "has_results": true, "last_update_posted_date": "2016-05-02", "last_synced_at": "2026-09-14T05:35:40.515Z", "location_count": 34, "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 24 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01363011" }, { "nct_id": "NCT01449929", "title": "Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Infection, Human Immunodeficiency Virus" ], "interventions": [ { "name": "dolutegravir 50 mg OAD", "type": "DRUG" }, { "name": "darunavir 800mg OAD", "type": "DRUG" }, { "name": "ritonavir 100mg OAD", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 488, "start_date": "2011-10-31", "completion_date": "2016-12-26", "has_results": true, "last_update_posted_date": "2018-01-16", "last_synced_at": "2026-09-14T05:35:40.515Z", "location_count": 33, "location_summary": "Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 25 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01449929" }, { "nct_id": "NCT01440569", "title": "Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acquired Immunodeficiency Syndrome", "HIV Infections" ], "interventions": [ { "name": "COBI", "type": "DRUG" }, { "name": "DRV", "type": "DRUG" }, { "name": "NRTIs", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 314, "start_date": "2011-09", "completion_date": "2015-10", "has_results": true, "last_update_posted_date": "2016-12-14", "last_synced_at": "2026-09-14T05:35:40.515Z", "location_count": 48, "location_summary": "Phoenix, Arizona • Long Beach, California • Los Angeles, California + 39 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01440569" } ] }